Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-05-06 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于2020年度权益分派实施的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the implementation of the 2020 annual equity distribution plan, including cash dividends and capital reserve to share capital conversion. It details the dividend amount, share capital changes, record dates, and dividend payment methods. The document is relatively short (2802 characters) and focuses on the dividend distribution details rather than presenting full financial statements or comprehensive annual results. It is not an annual report, earnings release, or interim report. It is a formal announcement of dividend amount and payment details following shareholder approval. Therefore, it fits the definition of a Notice of Dividend Amount (DIV).
2021-05-06 Chinese
关于公司部分董事、高级管理人员减持股份预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding the planned reduction of shares held by a company director and senior management personnel. It details the shareholder's identity, the number of shares to be reduced, the reasons for reduction, the method, and the timing. It references compliance with stock exchange rules and regulations about share reduction by insiders. There is no financial data, earnings information, or report content. The document is a notification of a director's personal share transaction plan, which fits the definition of Director's Dealing (DIRS). The document length is short and focused solely on this insider share reduction plan, confirming it is not a full report or announcement of a report publication.
2021-04-30 Chinese
关于2020年度股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 Annual General Meeting (AGM) of 安徽安科生物工程（集团）股份有限公司. It includes voting results on various proposals such as the 2020 board report, financial report, profit distribution plan, appointment of auditors, remuneration plans, amendments to the company charter, and other corporate governance matters. The document also describes the meeting logistics, attendance, and legal opinions confirming the validity of the meeting and resolutions. There is no full financial report or detailed financial statements included, but rather the outcomes of shareholder votes on these reports and other matters. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting. The document length (7395 characters) and content confirm it is not a brief report publication announcement or a full annual report. Therefore, the correct classification is DVA with high confidence.
2021-04-28 Chinese
关于安徽安科生物工程（集团）股份有限公司2020年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2020 Annual General Meeting (AGM) of Anhui Anke Biotechnology (Group) Co., Ltd. It details the legality and procedures of the AGM, including the convening, attendance, voting procedures, and resolutions passed. It does not contain the actual AGM materials or presentations but serves as a legal certification of the AGM process and results. The document length is 3166 characters, which is relatively short and focused on legal opinion rather than the full AGM materials. Therefore, it is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including legal opinions related to the AGM.
2021-04-28 Chinese
关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management member, specifically the company's vice president. It details the resignation, the effective date, and related shareholding information of the individual. There is no financial data, report, or presentation content. The document fits the category of announcements about changes in senior management or board members.
2021-04-27 Chinese
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled '安徽安科生物工程(集团)股份有限公司 2021 年第一季度报告全文' which translates to 'Anhui Anke Biotechnology (Group) Co., Ltd. 2021 First Quarter Report Full Text'. It contains detailed financial data for the first quarter of 2021, including revenue, net profit, cash flow, shareholder information, and detailed explanations of financial changes and business outlook. The presence of quarterly financial statements and substantive financial data confirms this is a comprehensive interim financial report. The length of the document (15,000 characters) and the detailed financial and operational data exclude it from being a mere announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.